Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 24k
27 February 2015
Question for written answer E-003233-15
to the Commission
Rule 130
Paloma López Bermejo (GUE/NGL)

 Subject:  The health costs of endocrine disrupting chemicals
 Answer in writing 

A recent report by the Health and Environment Alliance estimates that the health costs of endocrine disrupting chemicals (EDCs) amount to EUR 31 000 million per year in Europe. The serious effects of EDCs include fertility problems, cancer, behavioural problems, obesity and diabetes.

There are major delays affecting EU legislation on EDCs, including on the legal definition of them, and this has led to Sweden taking legal action against the Commission. Clear criteria for the definition of EDCs are vital to ensure that legislation can be put in place that reduces the risks of workers and consumers being exposed to them. With this in mind, the ongoing delays are not only illegal but also a serious threat to public health.

Following the conclusion of the public consultation on EDCs, what deadlines does the Commission have in place for the establishment of identification criteria for EDCs?

How can the Commission justify this major delay in coming up with criteria on EDCs, bearing in mind the deadlines laid down in its own regulations?

Original language of question: ES 
Legal notice - Privacy policy